The researchers prepared the nanoparticles, designated TA-AgNPs, by adding 1 mL of aqueous Trachyspermum ammi seed extract to 10 mL of 1.5 mM silver nitrate and stirring the mixture for five minutes at 25 °C. The solution changed from pale yellow to dark brown, a visible change the team treated as confirmation of reduction. UV-visible spectroscopy showed a prominent absorption peak at 420 nm. Dynamic light scattering and zeta analysis indicated a mean hydrodynamic diameter of 34.27 nm, an average zeta potential of −28 mV and a polydispersity index of 0.255. The particles were also characterized by scanning electron microscopy and Fourier-transform infrared spectroscopy, and the authors described them as spherical and nanoscale.

The seed extract was prepared by shaking 10 g of powdered T. ammi seeds in 100 mL of double-deionized water for approximately four hours at 37 °C before filtering the mixture. The researchers proposed that constituents associated with the plant’s essential oil, including thymol, p-cymene and gamma-terpinene, could serve as reducing agents during silver nanoparticle formation. Plant-mediated synthesis may also leave biologically active plant compounds associated with the silver surface, potentially influencing how the particles interact with cells. The experiment therefore tested TA-AgNPs as a combined product of silver and plant-derived material, but it did not isolate the effect of individual seed constituents or establish which chemical features were responsible for the observed activity.

In the cell-culture experiment, A431 human epidermal skin-cancer cells were exposed for 24 hours to TA-AgNPs at concentrations of 2.5, 5, 10, 20 and 25 micrograms per milliliter. Cell viability was assessed with the Alamar Blue assay, which detects the metabolic reduction of resazurin to fluorescent resorufin. Viability declined as nanoparticle concentration increased. At 20 micrograms per milliliter, viability averaged 20.2% for TA-AgNPs compared with 86.8% for the corresponding seed extract alone; at 25 micrograms per milliliter, the respective values were 11.9% and 87%. These differences were significant at p less than 0.01, whereas differences at 2.5, 5 and 10 micrograms per milliliter were reported as non-significant. The result supports a concentration-dependent cytotoxic effect in one human cancer cell line, but the supplied results include no non-cancer cell comparator, benchmark anticancer treatment or reported half-maximal inhibitory concentration.

For the animal experiment, 25 male Swiss albino mice aged six to seven weeks and weighing 28–35 g were divided into five groups of five. Skin carcinogenesis was induced by topical application of 7,12-dimethylbenz[a]anthracene, or DMBA, at 50 mg/kg, followed by 12-O-tetradecanoylphorbol-13-acetate, or TPA, at 0.01 micrograms per microliter three times weekly for 14 weeks. One group received only the carcinogens. Three intervention groups also received 0.1 mg/mL TA-AgNPs in carbopol gel, corresponding to 25 micrograms per kilogram per day: treatment began after DMBA, began after TPA, or continued throughout the full carcinogenesis protocol. A fifth group received TA-AgNPs without either carcinogen. The investigators measured tumor incidence, yield, burden, dimensions, weight, height and latency, along with liver superoxide dismutase activity, serum interleukin-6 and skin histopathology.

Continuous treatment produced the clearest change in tumor outcomes. All five mice in the carcinogen-only group developed tumors, with a reported tumor yield of 100%, an average tumor burden of five and tumors first appearing in week four. Their average latent period was five weeks. Starting TA-AgNPs after DMBA did not reduce incidence or yield, although tumor burden fell to 4.32 and the average latent period increased to six weeks. Starting treatment after TPA likewise left incidence and yield at 100%, while burden declined to 3.96 and latency increased to seven weeks. With TA-AgNPs administered throughout, tumor incidence and yield were each reported as 20%, average tumor burden fell to 1.71 and the average latent period reached nine weeks. The average tumor diameter changed little among carcinogen-exposed groups, remaining between 4.22 and 4.55 mm, indicating that the clearest measured effects involved the occurrence, number and timing of tumors rather than the size of tumors that did develop.

Oxidative-stress measurements suggested that the protective pattern depended on treatment duration. Liver superoxide dismutase activity fell to 25.52 ± 0.032 units per 50 microliters in the carcinogen-only group, compared with 34.90 ± 0.60 units per 50 microliters in untreated mice, a difference reported at p less than 0.01. TA-AgNPs introduced after DMBA or after TPA produced values of 45.22 ± 0.008 and 43.34 ± 0.005 units per 50 microliters, respectively, but neither differed significantly from the carcinogen control. Continuous TA-AgNP treatment raised activity to 55.41 ± 0.006 units per 50 microliters, a significant increase relative to the carcinogen group. The nanoparticle-only group measured 26.20 ± 0.049 units per 50 microliters and did not differ significantly from the carcinogen control. This pattern is consistent with an association among sustained administration, higher antioxidant-enzyme activity and reduced tumor burden, but the experiment does not establish that SOD upregulation caused the protective effect.

Serum interleukin-6 measurements showed that the anti-inflammatory interpretation was more limited. The cytokine rose to 181.60 ± 0.75 picograms per milligram of protein in the carcinogen-only group, compared with 63.30 ± 0.30 picograms per milligram in untreated mice. Beginning TA-AgNPs after DMBA failed to lower IL-6 and instead yielded 198.50 ± 0.85 picograms per milligram. Treatment after TPA reduced IL-6 to 163.20 ± 0.60 picograms per milligram, and continuous treatment produced a similar value of 162.80 ± 0.65 picograms per milligram; both were significantly lower than the carcinogen control at p less than 0.01, yet both remained well above the untreated baseline. Mice receiving TA-AgNPs without carcinogens had 65.20 ± 1.00 picograms per milligram, close to baseline. The data therefore indicate a partial, schedule-dependent reduction in IL-6 rather than elimination of the carcinogen-associated inflammatory environment.

Histopathological findings broadly supported the tumor measurements but also showed why the findings should not be described as a cure. Hematoxylin-and-eosin-stained skin sections contained squamous-cell-carcinoma features and keratin pearls in the carcinogen-only group and in each group that received TA-AgNPs alongside carcinogens, although the extent differed among treatment schedules. In the nanoparticle-only group, no tumors appeared, no keratin pearls were observed and epithelial architecture remained preserved. Quantitative results were summarized as means with standard deviations and compared through one-way analysis of variance followed by Tukey’s post hoc honestly significant difference test; the cell assay used three replicates. The small animal number, use of only one sex and one chemically induced mouse model, absence of a clinical comparator, and lack of long-term toxicity or pharmacokinetic analysis limit translation. The study identifies plant-mediated nanosilver as an experimental chemopreventive candidate, but it does not establish efficacy, safety or dosing for people with cancer.

Subject of Research: Experimental evaluation of Trachyspermum ammi-mediated silver nanoparticles for skin-cancer chemoprevention

Article Title: Trachyspermum ammi seed extract modulated nanosilver as a transformative agent for anticancer activity

Article References: Saxena, N., Jain, S., Yadav, N., Sharma, B., Kasodekar, S. A., Gupta, N., & Chatterjee, S. (2026). Trachyspermum ammi seed extract modulated nanosilver as a transformative agent for anticancer activity. Frontiers in Biomaterials Science, 5, Article 1942456. https://doi.org/10.3389/fbiom.2026.1942456

Image Credits: AI Generated

DOI: 10.3389/fbiom.2026.1942456

Keywords: Trachyspermum ammi, silver nanoparticles, green synthesis, skin cancer, A431 cells, DMBA-TPA model, tumor incidence, antioxidant defense, interleukin-6, mouse model, Trachyspermum, ammi

Patients were excluded if they had incomplete data, acute infection or inflammatory conditions, autoimmune disease or another concurrent malignancy. They received chemotherapy alone (n=31), pembrolizumab plus chemotherapy (n=39), or atezolizumab plus chemotherapy (n=50), with treating oncologists making treatment decisions according to institutional clinical practice guidelines. The three groups did not differ significantly in baseline age, sex, smoking status or PD-L1 expression.

Tumor response was evaluated using RECIST version 1.1, while pulmonary function was assessed by forced expiratory volume in 1 second as a percentage of predicted value. Blood was collected on day 10 after the sixth treatment cycle between 9:00 and 10:00 a.m. Serum IL-6 was measured with an enzyme-linked immunosorbent assay, for which the reported detection range was 4.69–300 pg/mL and sensitivity was 2.8 pg/mL.

Patients were also assessed with routine blood counts, including hemoglobin, platelet count and neutrophil-to-lymphocyte ratio (NLR). Response distributions differed significantly among the treatment groups (p < 0.001). Progressive disease occurred in 48.4% of the chemotherapy group, 15.4% of the pembrolizumab group and 8.0% of the atezolizumab group.

Objective response, comprising complete or partial response, was reported in 16.1%, 61.5% and 60.0% of the respective groups. Disease control, defined as complete response, partial response or stable disease, was 51.6%, 84.6% and 92.0%, respectively. These were descriptive comparisons in nonrandomized treatment groups and do not establish comparative treatment efficacy.

Median post-treatment IL-6 concentrations also differed by treatment group: 16.5 pg/mL with chemotherapy, 12.5 pg/mL with pembrolizumab plus chemotherapy and 10.0 pg/mL with atezolizumab plus chemotherapy (p < 0.001). When patients were grouped by response, those with complete or partial response had a median IL-6 concentration of 9.23 pg/mL, compared with 15.7 pg/mL among those with stable or progressive disease (p < 0.001). These values were group medians with interquartile ranges, rather than average concentrations.

Receiver operating characteristic analysis estimated the ability of post-treatment IL-6 to discriminate progressive disease from non-progressive disease, with an area under the curve of 0.961 (95% confidence interval, 0.909–0.988). A threshold above 15.5 pg/mL had a reported sensitivity of 91.6% and specificity of 96.0%. This was an in-sample analysis in the treated cohort, and the reported performance has not established IL-6 as a validated clinical test.

Multivariable logistic regression retained an association between IL-6 and progressive disease. For each 1 pg/mL increase in IL-6, the adjusted odds ratio for progression was 1.72 (95% confidence interval, 1.34–2.21; p < 0.001). The NLR was associated with progression in the univariate analysis, with an odds ratio of 3.00 per one-unit increase (95% confidence interval, 1.88–4.80; p < 0.001), but it was not independently associated after adjustment (adjusted odds ratio 1.39; 95% confidence interval, 0.79–2.44; p=0.24).

Platelet count and FEV1 as a percentage of predicted also were not independently associated with progression. The findings are observational and do not establish that elevated IL-6 causes progression, that IL-6 is a cause-specific marker, or that measuring it would improve clinical decisions. The study did not assess longitudinal changes in IL-6, and the sample of 120 patients may limit subgroup analyses and generalizability.

All participants had COPD, and the results came from two Iraqi oncology centers, so applicability to patients without COPD or to other health systems requires assessment. The authors stated that the findings require confirmation in larger prospective longitudinal studies before IL-6 can be incorporated routinely into risk stratification or used to guide treatment decisions.

Subject of Research: Post-treatment serum IL-6 and progression in advanced NSCLC with COPD

Article Title: Post-treatment serum interleukin-6 is independently associated with disease progression in patients with advanced non-small cell lung cancer and coexisting COPD: a multicenter real-world cohort study

Article References: Kareem, A. H., Mohammed, S. I., & Shihad, A. A. (2026). Post-treatment serum interleukin-6 is independently associated with disease progression in patients with advanced non-small cell lung cancer and coexisting COPD: a multicenter real-world cohort study. Pharmacia, 73, Article e194159. https://doi.org/10.3897/pharmacia.73.e194159

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e194159

Keywords: NSCLC, COPD, interleukin-6, disease progression, chemotherapy, immune checkpoint inhibitors, observational cohort, risk stratification, Post-treatment, serum, independently, associated

Patients had to remain in the intensive care unit for at least 24 hours. The investigators analysed each marker using the first value obtained after ICU admission, recorded at a median of 0.6 hours with an interquartile range of 0.5 to 4.5 hours, and, in parallel, the worst value within the first 24 hours. They compared discrimination using area under the receiver-operating-characteristic curve (AUC) and the DeLong test, overall and within severity strata and by admission source. The septic-shock approximation was based on vasopressor use and a first post-ICU venous lactate above 2 mmol/L.

With first measurements, CRP had an AUC of 0.504 (95% confidence interval, 0.439 to 0.567) and PCT had an AUC of 0.549 (0.486 to 0.614), both at or near chance-level discrimination. The NLR point estimate was below chance at 0.438 (0.371 to 0.501), although its confidence interval included 0.50. IL-6 had an AUC of 0.694 (0.631 to 0.756), and venous lactate had an AUC of 0.682 (0.622 to 0.742). Results were similar when the worst values within 24 hours were used, with all paired DeLong p values of at least 0.19.

Adding first IL-6 and lactate values to a partially window-aligned clinical model increased AUC from 0.782 to 0.808. The likelihood-ratio p value was 0.0004, while the DeLong comparison yielded p = 0.057. Performance was weaker among the 92 patients who did not meet the septic-shock approximation: AUC was 0.578 for IL-6 and 0.502 for lactate. The authors said this attenuation meant that restriction to a narrow, high-severity case mix could not be excluded as an explanation. By contrast, assay censoring appeared insufficient to explain the limited prognostic information associated with CRP and neutrophil-based indices: CRP and NLR were not significantly correlated with reconstructed SOFA, and only 1.3% of first CRP values reached the assay ceiling. These findings come from a retrospective analysis summarized in the abstract; they do not establish prospective performance beyond the included high-acuity ICU population, and the authors called for prospective evaluation.

Subject of Research: Retrospective comparison of inflammatory markers, IL-6 and lactate for predicting 28-day mortality in high-acuity ICU sepsis

Article Title: Head-to-head comparison of routinely ordered inflammatory markers, interleukin-6 and lactate for 28-day mortality in high-acuity ICU sepsis: a predominantly vasopressor-treated cohort

Article References: Feng, L., Xie, Q., Wang, Y., & Li, K. (2026). Head-to-head comparison of routinely ordered inflammatory markers, interleukin-6 and lactate for 28-day mortality in high-acuity ICU sepsis: a predominantly vasopressor-treated cohort. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14472-3

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14472-3

Keywords: sepsis, intensive care, 28-day mortality, interleukin-6, venous lactate, C-reactive protein, procalcitonin, neutrophil-to-lymphocyte ratio, vasopressors, retrospective cohort, Head-to-head, comparison

Aortic stenosis has long been viewed as a mechanical problem: calcium accumulates on the aortic valve over decades, the valve opening narrows, and the heart struggles to push blood through. But the new study reinforces a very different picture that has been emerging over the past two decades. Degenerative aortic stenosis is an actively inflammatory process, sharing many of the same cellular and molecular players that drive atherosclerosis, including oxidized lipids, monocytes, T lymphocytes, and pro-inflammatory signaling cascades. The authors frame this within the concept of inflammaging, the chronic, low-grade, sterile inflammation that rises with age and feeds a vicious cycle accelerating structural cardiovascular changes, cardiometabolic disease, and valvular calcification simultaneously.

The RCII is designed to quantify precisely that intersection. It is calculated as the product of remnant cholesterol, the cholesterol carried in triglyceride-rich lipoprotein particles, and high-sensitivity C-reactive protein, divided by ten. Remnant cholesterol is obtained by subtracting HDL and LDL cholesterol from total cholesterol, making it derivable from any standard lipid panel. Remnant particles are considered highly atherogenic because they infiltrate the arterial intima, activate vascular and immune cells, and promote endothelial dysfunction and cholesterol deposition. C-reactive protein, meanwhile, is a hallmark of inflammaging, activating the complement system, recruiting macrophages to arterial walls, and promoting cytokine production and plaque vulnerability. Multiplying the two creates an index that reflects the joint burden of lipid-driven and inflammation-driven vascular injury.

The study population consisted of elderly patients, averaging 83.5 years of age and predominantly female, referred to the outpatient clinic of the Ospedale del Cuore in Massa, Italy, between March 2016 and March 2020. All had severe aortic stenosis with preserved left ventricular systolic function and underwent a multidisciplinary heart team evaluation including clinical, surgical, laboratory, and multidimensional geriatric assessment. The cohort carried a heavy cardiometabolic burden: 88 percent had hypertension, 74 percent had dyslipidemia, and 36 percent had type 2 diabetes. Frailty was assessed using the Fried phenotype criteria, and every patient was classified as at least pre-frail. Patients with acute heart failure, hemodynamic shock, or active infection were excluded to avoid distorting the inflammatory biomarkers under study.

The correlation analysis produced a strikingly coherent pattern. RCII levels correlated most strongly with interleukin-6, a central pro-inflammatory cytokine, with a correlation coefficient of 0.6, and also showed significant positive associations with neutrophils, the neutrophil-to-lymphocyte ratio, monocytes, platelets, erythrocyte sedimentation rate, and fibrinogen. Positive correlations, albeit weaker, emerged with glucose and creatinine, pointing toward disturbed glucose metabolism and renal involvement. The index also correlated with vascular endothelial growth factor, a mediator of the angiogenesis that occurs within calcified valves, and with frailty scores, suggesting that RCII may capture a multisystem vulnerability rather than a single disease process. Inverse correlations appeared with albumin, which typically falls during inflammatory states, and with HDL cholesterol, indicating that a high RCII reflects an unfavorable metabolic profile.

The survival findings carried the study’s most consequential implication. Over a mean follow-up of 19 months, ten cardiovascular deaths occurred. Kaplan-Meier analysis showed significantly worse survival among patients whose RCII exceeded the 75th percentile, a threshold of 17.6. In an exploratory multivariable Cox regression, higher RCII remained associated with cardiovascular mortality with a hazard ratio of 3.5, alongside elevated neutrophil counts, which showed a hazard ratio of 5.1. The authors are careful to stress, however, that the confidence interval for the RCII estimate was wide, spanning from 1.0 to 12.0, and that the small number of deaths limits statistical power. They explicitly describe the association as exploratory and hypothesis-generating rather than evidence of an established independent prognostic role.

Beneath the statistical associations lies a plausible molecular mechanism centered on the NLRP3 inflammasome, a multiprotein complex that, when activated, triggers caspase-1 and drives the release of pro-inflammatory cytokines such as interleukin-6, prompting the liver to produce C-reactive protein and fibrinogen. Oxidized LDL particles are important regulators of this inflammasome, making it a candidate link between the cholesterol pathway and vascular inflammation. In the context of aortic stenosis, NLRP3 activation promotes the transformation of valvular interstitial cells into bone-like cells, driving osteogenic calcification, and experimental studies have shown that blocking the inflammasome can reduce or reverse valve calcification in animal models. The same pathway has been implicated in frailty, sarcopenia, and cognitive decline, which may explain why a biomarker combining lipid and inflammatory signals tracked so closely with frailty in this cohort.

This mechanistic overlap also opens a therapeutic horizon. Drugs that target the NLRP3 inflammasome or its downstream interleukin-1 signaling, including anakinra, colchicine, canakinumab, and rilonacept, could in principle counteract inflammaging, atherosclerosis, and valvular calcification simultaneously. The authors also note that RCII is actionable in a broader sense, since both of its components can be modified by lipid-lowering and anti-inflammatory strategies or lifestyle changes. Yet they caution that therapies effective in atherosclerosis have not consistently shown benefit in aortic stenosis, and no pharmacological treatment currently exists to prevent or delay the progression of calcific valve disease, which is why sensitive biomarkers capable of detecting early, still-modifiable disease stages are so urgently needed.

The study has important limitations that the authors confront directly. It was retrospective, IL-6 and VEGF were measured in only 23 of the 103 patients, and the low number of cardiovascular deaths raises the risk of model instability and overfitting in the multivariable analysis. The study also cannot establish whether RCII adds predictive information beyond established clinical variables such as age, frailty, diabetes, renal function, BNP, aortic valve gradient, prior myocardial infarction, and treatment strategy. Before any clinical adoption, the authors call for external validation, standardized thresholds, serial measurements, and head-to-head comparison with established risk prediction models.

Even with those caveats, the appeal of RCII is hard to ignore. It requires no new technology, no specialized assay, and no additional blood draw, being computable from a routine lipid panel and a standard C-reactive protein measurement. Prior studies have linked the index to stroke risk, all-cause and cardiovascular mortality, metabolic syndrome, diabetes incidence, and short-term mortality in acute decompensated heart failure, with some large population analyses finding nearly sevenfold higher odds of metabolic syndrome in the highest RCII quartile. If larger prospective studies confirm the Italian team’s preliminary signal, this low-cost index could help clinicians identify which elderly patients with aortic stenosis carry the greatest hidden inflammatory-metabolic risk, opening a window for earlier, personalized prevention in a population where every month of modifiable risk matters.

Subject of Research: The remnant cholesterol inflammatory index as a predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article Title: Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article References: Mazzone, A., Gaggini, M., Foffa, I., Del Turco, S., Minichilli, F., Berti, S., & Vassalle, C. (2026). Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis. Frontiers in Endocrinology, 17, Article 1894558. https://doi.org/10.3389/fendo.2026.1894558

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1894558

Keywords: aortic stenosis, remnant cholesterol inflammatory index, inflammaging, cardiovascular mortality, C-reactive protein, frailty, NLRP3 inflammasome, cardiometabolic risk, elderly patients, biomarker, interleukin-6, valve calcification

The study, published in Clinical Research in Cardiology, followed 113 patients treated with an Impella microaxial flow pump between January 2021 and December 2023. All patients had cardiogenic shock classified as stage C or higher on the Society for Cardiovascular Angiography and Interventions scale, meaning their circulatory failure was severe enough to require mechanical assistance. The researchers measured four cytokines, interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor-α, at five predefined time points: at device implantation and then at 24, 72, 120, and 168 hours afterwards. Serum samples were analyzed using chemiluminescent immunoassays on a Siemens IMMULITE 2000 XPi system, allowing precise quantification of even low cytokine concentrations.

The biological rationale for the study rests on a growing recognition that cardiogenic shock is more than a plumbing failure. Myocardial ischemia and reperfusion release damage-associated molecular patterns that activate innate immune pathways, triggering a flood of proinflammatory mediators. These cytokines, including interleukin-6 and tumor necrosis factor-α, are associated with myocardial depression, vasoplegia, endothelial dysfunction, and microcirculatory impairment, all of which are closely linked to organ failure and death. The problem is that current shock classification frameworks, such as the SCAI staging system and guideline-based strategies from the American and European cardiology societies, rely almost exclusively on hemodynamic and metabolic parameters. They capture how badly the circulation is failing but say little about the underlying inflammatory injury that may be driving the patient toward irreversible decline.

The results revealed a clear temporal pattern. At the moment of implantation, tumor necrosis factor-α was the only cytokine significantly elevated in patients who would later die. By 24 hours, both interleukin-6 and tumor necrosis factor-α were higher in non-survivors. The divergence peaked at 72 hours, driven overwhelmingly by interleukin-6, which showed the most pronounced, sustained, and temporally consistent separation of any molecule measured. At 120 hours, interleukin-6 remained the only cytokine still discriminating between outcomes, and by 168 hours no cytokine showed significant differences. Interleukin-1β never differed between groups at any time point, likely because it is released locally and transiently, whereas interleukin-6 acts as a downstream amplifier that better reflects sustained systemic inflammation.

The statistical analysis strengthened the clinical significance of this signal. Using time-point-specific multivariable logistic regression models designed to avoid collinearity between repeated measurements, the researchers found that log-transformed interleukin-6 was already an independent predictor of 30-day mortality at 24 hours, with an odds ratio of 3.07. At 72 hours, the model was most robust: interleukin-6 carried an odds ratio of 4.68 and lactate an odds ratio of 2.74, while C-reactive protein and procalcitonin lost their significance. Receiver operating characteristic analysis at 72 hours yielded an area under the curve of 0.745 and identified an optimal cut-off of 164.5 picograms per milliliter, with 68.0 percent sensitivity and 82.1 percent specificity. In exploratory landmark-type Kaplan–Meier analysis, patients above this threshold had markedly lower 30-day survival, with a log-rank p value below 0.001.

Perhaps most importantly, interleukin-6 added prognostic value beyond the markers clinicians already use. The researchers compared a base model containing age, lactate, and the vasoactive-inotropic score, a composite measure of pharmacological hemodynamic support, against an extended model that also included interleukin-6. Adding the cytokine improved the area under the curve from 0.79 to 0.82 and significantly improved overall model fit according to the likelihood-ratio test. Notably, the vasoactive-inotropic score was no longer statistically significant in the fully adjusted model, suggesting that the inflammatory signal captured information about patient trajectory that the intensity of drug support alone could not. Interaction analyses showed that the association between interleukin-6 and mortality was not modified by hemodynamic severity or by blood culture positivity.

That last finding addresses one of the thorniest questions in shock medicine: is the inflammation driven by the shock itself, or by a hidden infection? Blood cultures were obtained in 90 of the 113 patients, and 16 of those cultures were positive, predominantly with gram-positive organisms such as Staphylococcus epidermidis and Cutibacterium acnes. There was no difference in culture positivity between survivors and non-survivors, and interleukin-6 concentrations showed no consistent association with blood culture status. The authors are careful, however, not to overinterpret this. Blood cultures are an imperfect marker of infection, and the retrospective design meant that culture-negative infections, contamination, ventilator-associated infections, and the effects of antibiotic exposure could not be systematically excluded. Persistent interleukin-6 elevation, they conclude, should be read as a marker of ongoing inflammatory activation that may reflect sterile shock inflammation, unrecognized infection, or vasoplegic physiology.

The study also offers a window into how the devices themselves might interact with the immune system. Non-survivors required higher pump performance levels at the first follow-up assessments, likely reflecting higher rotational speeds, and non-physiological shear stress and hemolysis are known to modulate inflammatory signaling. Yet because every patient in the cohort received a microaxial pump and there was no control group, the study cannot determine whether the support itself attenuates, amplifies, or merely accompanies the inflammatory response. The cohort also had a comparatively low 30-day mortality rate of 26.5 percent, which the authors attribute to selection: patients on veno-arterial ECMO, those supported for less than 24 hours, and the most refractory stage E patients were all excluded. Non-survivors in the study were older, had lower ejection fractions, higher SOFA scores, and more often required continuous hemodiafiltration, consistent with greater baseline vulnerability.

The findings arrive at a moment when the field is recalibrating its expectations for mechanical circulatory support. The randomized DanGer Shock trial demonstrated that microaxial pump support can improve outcomes in selected patients with infarct-related shock, but benefit depends on timing, etiology, and overall severity, while the CHIP-BCIS3 trial of elective unloading during complex percutaneous coronary intervention did not reduce major adverse events. Against that backdrop, the Marburg results suggest that biology, not just hemodynamics, may determine who benefits. The authors emphasize that interleukin-6 at 72 hours should not be used as the sole criterion for starting, withholding, or modifying support. Instead, a persistently elevated value should trigger structured clinical reassessment, including evaluation of support adequacy, catecholamine exposure, residual ischemia, infection, and device complications.

The study’s limitations are acknowledged candidly. It was single-center and retrospective, exact intervals from symptom onset to implantation were unavailable, and attrition reduced statistical power at later time points. Only preselected cytokines were measured, leaving out potentially relevant mediators such as interleukin-10, and serial cardiac biomarkers were not standardized across all time points. The 164.5 picogram per milliliter threshold requires external validation and assay standardization before it can enter routine practice. Still, the central message is compelling: in patients whose hearts are being mechanically supported, the immune system’s trajectory over the first three days tells a story that blood pressure and lactate alone cannot. Serial interleukin-6 measurement, the authors conclude, is a hypothesis-generating tool that may finally give clinicians a biological window into which shock patients are recovering and which are quietly sliding toward a fate that no pump, however sophisticated, can reverse on its own.

Subject of Research: Cytokine trajectories and inflammatory risk stratification in cardiogenic shock patients supported by microaxial flow pumps

Article Title: Temporal cytokine trajectories during microaxial flow pump support identify a high-risk inflammatory phenotype in cardiogenic shock

Article References: Kreutz, J., Amoah, J., Mihali, K., Harbaum, L., Chatzis, G., Patsalis, N., Syntila, S., Schieffer, B., & Markus, B. (2026). Temporal cytokine trajectories during microaxial flow pump support identify a high-risk inflammatory phenotype in cardiogenic shock. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03040-z

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03040-z

Keywords: cardiogenic shock, interleukin-6, microaxial flow pump, mechanical circulatory support, cytokines, inflammation, prognostic markers, 30-day mortality, Impella, biomarkers, SCAI classification, lactate

The biology behind this adverse reaction begins with the normal physiology of interleukin-6, a signaling molecule that acts on hepatocytes to drive the acute-phase response. When inflammation flares, IL-6 prompts the liver to ramp up production of fibrinogen, C-reactive protein, and other acute-phase proteins, which is why fibrinogen levels typically rise during active inflammatory states. Tocilizumab interrupts this pathway by binding the IL-6 receptor, and the resulting suppression of hepatic fibrinogen synthesis is generally regarded as a pharmacological effect rather than an idiosyncratic reaction. In most patients this effect is modest and clinically silent, but in a subset the decline is pronounced enough to constitute hypofibrinogenemia, defined in many laboratories as a concentration below 1.5 g/L. The case patient’s pretreatment value of 3.29 g/L sat comfortably within the normal range, and her fall to 0.85 g/L within roughly a month of re-exposure represents a drop of more than seventy percent, a magnitude that would ordinarily raise concern about spontaneous bleeding even though none was observed.

What makes the fibrinogen decline during tocilizumab therapy difficult to interpret at the bedside is that the drug simultaneously suppresses inflammation, which would normally be expected to lower fibrinogen toward baseline rather than below it. The distinction lies in the degree and tempo of the fall. A gradual drift from a mildly elevated value back toward the normal range is expected with effective anti-inflammatory treatment, whereas a steep descent below the reference interval, particularly one that continues after inflammatory markers have already normalized, suggests that IL-6 receptor blockade has unmasked or exaggerated an underlying limitation in fibrinogen production. In this patient, the concurrent laboratory picture offered some reassurance: liver enzymes remained essentially normal at both nadirs, with AST of 24 U/L and ALT of 14 U/L at the first nadir and 29 and 19 U/L at the second, arguing against hepatic synthetic failure as an alternative explanation. Albumin was mildly low at 31.3 g/L, which could reflect chronic disease and inflammation, but the isolated and reproducible nature of the fibrinogen decline, together with its reversal after drug withdrawal, points to a drug-related mechanism rather than a deteriorating liver.

The coagulation profile obtained at the second nadir adds further nuance. Prothrombin time was 11.8 seconds with an international normalized ratio of 0.97, and activated partial thromboplastin time was 21.6 seconds, both within conventional limits. This apparent paradox, in which fibrinogen is markedly reduced yet standard clotting times remain normal, is well recognized. Clotting assays are calibrated against pooled normal plasma, and because fibrinogen is the final common substrate of both the intrinsic and extrinsic pathways, these times often remain preserved until fibrinogen falls to extremely low concentrations, sometimes below 0.5 g/L. Thrombin time, which was prolonged at 25.5 seconds, is more sensitive to fibrinogen availability and can serve as an early clue. The elevated D-dimer of 3,626 μg/L FEU reflects ongoing fibrin turnover, which may be driven by the inflammatory state itself, and complicates the interpretation of fibrinogen dynamics because consumption and impaired production can coexist. Clinicians monitoring patients on tocilizumab therefore cannot rely on routine clotting screens alone and should consider direct fibrinogen measurement when unexplained bruising, mucosal bleeding, or laboratory anomalies appear.

The management decisions in this case illustrate the limited evidence base guiding treatment of tocilizumab-associated hypofibrinogenemia. After the first episode, the team withheld the drug and administered 20 units of cryoprecipitate, a plasma-derived concentrate rich in fibrinogen, factor VIII, von Willebrand factor, and factor XIII. Fibrinogen rose from 0.85 to 1.99 g/L within two days, but the subsequent trajectory, with values of 1.49, 1.85, and 2.07 g/L over the following seven weeks in the absence of further replacement, indicates that endogenous hepatic synthesis recovered once the pharmacological brake was removed. Notably, after the second episode the team chose observation alone, and fibrinogen still climbed from 1.05 to 1.28 g/L and then to 2.45 g/L by late September without any replacement therapy. This spontaneous recovery on both occasions reinforces the view that the effect is reversible and dose-dependent, and it suggests that cryoprecipitate is generally reserved for patients with very low levels or active bleeding rather than administered reflexively.

The question of whether dose reduction can prevent recurrence is central to this report, because it has never been clearly answered in the literature. The patient originally received 400 mg intravenously every four weeks, a dose below the standard 8 mg/kg regimen for her 56 kg body weight, which would have been approximately 448 mg. The rechallenge dose of 240 mg represented a forty percent reduction, yet hypofibrinogenemia still developed, albeit less severely, with a nadir of 1.05 g/L compared with 0.85 g/L during the first episode. The interval to nadir was also compressed, occurring 17 days after re-exposure rather than roughly a month. One plausible interpretation is that the first episode in 2026 was itself a recurrence of an unappreciated effect during the initial treatment course in 2024, when the patient received tocilizumab for about six months. Fibrinogen values recorded that year ranged from 2.21 to 4.36 g/L without a persistent downward pattern, but the available measurements may have been too infrequent to capture transient dips, and the drug was stopped for financial reasons rather than for safety concerns. If true, this would suggest that susceptibility to the effect is a stable individual trait rather than a random event, and that prior tolerance does not guarantee future tolerance.

The patient’s broader clinical context deserves attention because several features may have modulated her risk. She had a 13-year history of seropositive rheumatoid arthritis with high-titer rheumatoid factor and anti-cyclic citrullinated peptide antibodies, coexisting interstitial lung disease that precluded methotrexate, and a treatment history marked by intolerance and complications, including cervical lymph-node tuberculosis during infliximab therapy and a pruritic rash on iguratimod. Intermittent thrombocytopenia predated the 2026 tocilizumab reinitiation and persisted throughout, with platelet counts declining from 60 to 50 × 10^9/L across the observation period. Thrombocytopenia and hypofibrinogenemia together would ordinarily compound bleeding risk, yet the patient remained free of clinically evident bleeding at every stage, which is somewhat reassuring but also reflects the fact that fibrinogen levels above 1.0 g/L are often sufficient for hemostasis in stable patients. A bone marrow examination was considered but deferred because of the bleeding risk associated with severe thrombocytopenia, leaving the platelet decline without a definitive explanation, though chronic inflammation and drug effects are both plausible contributors.

From a surveillance standpoint, the case supports a practical monitoring framework for clinicians using tocilizumab. Because fibrinogen is not part of most standard pre-infusion panels, it may be worth adding to the laboratory schedule for patients beginning therapy, establishing a baseline against which later values can be judged. The timing of the declines in this patient, roughly three to four weeks after infusion in the first episode and just over two weeks after rechallenge, suggests that a check performed midway between infusions would be well positioned to catch a developing nadir before it becomes severe. The absence of bleeding symptoms in both episodes should not breed complacency, since spontaneous hemorrhage becomes a realistic concern once fibrinogen falls below approximately 0.5 to 1.0 g/L, particularly in elderly patients who may have additional vascular fragility or who require anticoagulation for comorbid conditions.

The causality assessment performed by the authors, using both the Naranjo algorithm and the WHO-UMC criteria, yielded a probable rating, which is the highest category typically achievable in the absence of rechallenge data, and the deliberate rechallenge here strengthens the inference considerably. The temporal sequence is clear, the effect reproduced at a lower dose, and alternative explanations such as liver disease, disseminated intravascular coagulation, or consumptive coagulopathy were reasonably excluded by the laboratory findings. The Naranjo algorithm assigns points for previously reported reactions, and hypofibrinogenemia during tocilizumab therapy has indeed been described in case series and real-world cohorts, though the frequency, severity thresholds, and management approaches vary widely across studies. Some real-world analyses suggest the phenomenon is not rare, which raises the question of whether routine fibrinogen monitoring should be considered for all patients on long-term IL-6 blockade rather than only for those with symptoms.

For patients like this woman, whose disease remained highly active with a DAS28 of 5.8 despite prednisone, iguratimod, and Tripterygium wilfordii, the therapeutic options after tocilizumab withdrawal are constrained. Her prior intolerance to iguratimod at higher exposure, her contraindication to methotrexate because of interstitial lung disease, and her adverse experience with a tumor necrosis factor inhibitor narrow the field considerably. Other biologics with different mechanisms, such as B-cell depletion or T-cell costimulation blockade, or targeted synthetic agents, may be considered, each with its own risk profile in a patient with interstitial lung disease and a history of tuberculosis. The decision to rechallenge with tocilizumab at a reduced dose was a reasoned attempt to retain clinical benefit while limiting toxicity, and the improvement in joint symptoms alongside the fall in inflammatory markers, with erythrocyte sedimentation rate dropping from 34 to 10 mm/h and C-reactive protein from 9.05 to 1.21 mg/L, confirms that even the reduced dose retained substantial efficacy. The trade-off, however, was a predictable recurrence of the fibrinogen decline, and the ultimate decision to withhold the drug again reflects the difficulty of balancing disease control against an adverse effect that, while rarely symptomatic in this patient, carries the potential for serious hemorrhagic complications if left unmonitored.

The broader lesson from this report is that hypofibrinogenemia during tocilizumab therapy deserves a place in the differential diagnosis of abnormal coagulation tests in treated patients, and that a prior episode should prompt heightened vigilance rather than reassurance if re-exposure is attempted. Dose reduction, while intuitively appealing, did not prevent recurrence here, and the compressed interval to the second nadir suggests that susceptibility may persist or even intensify with repeated exposure. Until larger datasets clarify which patients are at highest risk and whether any dosing strategy can reliably avoid the effect, individualized monitoring of fibrinogen, particularly in the weeks following initiation or reinitiation, remains the most defensible approach for clinicians managing patients who require this otherwise effective therapy.

Subject of Research: Recurrent tocilizumab-associated hypofibrinogenemia in rheumatoid arthritis after reduced-dose rechallenge

Article Title: Recurrent hypofibrinogenemia after reduced-dose tocilizumab rechallenge in rheumatoid arthritis: a case report

Article References: Li, Y., Yan, Y., Zhou, H., Fu, E., & Zheng, M. (2026). Recurrent hypofibrinogenemia after reduced-dose tocilizumab rechallenge in rheumatoid arthritis: a case report. Frontiers in Pharmacology, 17, 1981054. https://doi.org/10.3389/fphar.2026.1981054

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1981054

Keywords: tocilizumab, hypofibrinogenemia, rheumatoid arthritis, interleukin-6, fibrinogen, drug safety, case report, rechallenge, pharmacovigilance, biologic therapy, coagulation, immunology

The study, conducted at Chiba University in collaboration with Asahi General Hospital and International University of Health and Welfare Narita Hospital, was led by Assistant Professor Shigeru Tanaka and Professor Hiroshi Nakajima of the Graduate School of Medicine at Chiba University. Their findings, published in the journal Science Advances on October 16, 2026, identify a stress-responsive pathway that depends on the inflammatory signaling protein interleukin-6, or IL-6. The work provides what the researchers describe as a biological explanation for how psychological stress can reactivate joint inflammation independently of the lymphocytes traditionally blamed for autoimmune disease.

To capture the phenomenon of stress-induced flares, the team used a mouse model of autoimmune arthritis in which the disease was first allowed to enter a remission-like state. The animals were then exposed to restraint stress, a standard laboratory method for inducing psychological stress in rodents. Following the stress exposure, the researchers observed that inflammation flared back to life in joints that had previously quieted down. This experimental design was critical, because it separated the question of how stress initiates arthritis from the arguably more puzzling question of how stress resurrects inflammation in tissue that appeared to have healed.

Using tissue analysis, immune-cell profiling, and molecular measurements, the researchers traced the inflammatory signals activated by stress. The experiments revealed that psychological stress switches on the sympathetic nervous system, the branch of the nervous system responsible for the fight-or-flight response. This activation targets brown adipose tissue, a specialized form of body fat best known for generating heat. When stimulated by stress-related neural signals, the brown fat releases IL-6 into the circulation, turning a fat depot into an unexpected source of inflammatory signaling. The observation suggests that the effects of stress on arthritis extend well beyond the immune cells conventionally associated with autoimmunity.

The next question was which cells inside the joint respond to this circulating IL-6. The answer pointed to fibroblast-like synoviocytes, specialized cells embedded in the synovial tissue that lines and lubricates the joints. IL-6 stimulates these cells to produce CXCL1, a chemokine that functions as a biological beacon for neutrophils, the white blood cells that act as early responders in inflammatory reactions. Attracted by CXCL1, neutrophils flood into the joint, and their accumulation drives the reactivation of inflammation. When the researchers blocked the CXCR2 receptor, which responds to CXCL1, stress-triggered arthritis in the mouse model was significantly reduced.

The team then tested the pathway at multiple points by blocking key receptors and monitoring inflammatory markers, joint swelling, and immune-cell accumulation. When mice were treated with a β3-adrenergic receptor antagonist, a compound that interferes with the stress-related neural signal reaching brown adipose tissue, the researchers observed a coordinated decline across the entire pathway: plasma IL-6 levels dropped, joint swelling diminished, CXCL1 expression fell, and neutrophil accumulation in the joints decreased. The results establish the sequence as a coherent causal chain rather than a loose collection of correlations.

The implications reach beyond laboratory mice. The researchers examined whether this stress-related pathway leaves traces in people with rheumatoid arthritis by analyzing a specific variant of the ADRB3 gene, which encodes the β3-adrenergic receptor. Patients carrying the Trp64Arg variant, which makes cells less responsive to stress-related hormones, showed a weaker link between perceived stress and arthritis activity compared with patients without the variant. The researchers caution that this analysis was observational, so it does not prove that stress directly caused changes in disease activity, but the genetic association offers suggestive human evidence that the pathway identified in mice may be relevant to patients.

One of the most conceptually important findings is the idea that arthritic joints may retain a form of tissue inflammatory memory. According to this view, the joint tissue itself preserves a capacity for inflammation that persists after the visible disease has remitted, and this memory can be reactivated by stress through a pathway that operates independently of lymphocytes. The concept reframes remission not as a complete return to health but as a dormant state in which the joint remains primed for reactivation, with fibroblast-like synoviocytes serving as the tissue-resident switch that stress can flip.

The therapeutic possibilities emerging from this work are notable precisely because the pathway offers a way to intervene without broadly suppressing the immune system. Current rheumatoid arthritis treatments rely heavily on immunosuppression, which leaves patients vulnerable to infections. Targeting the stress-responsive arm of this pathway, for example by modulating β3-adrenergic signaling, IL-6 release, or the CXCL1-CXCR2 axis, could in principle calm stress-triggered flares while leaving the rest of the immune defenses intact. The mouse experiments, in which receptor blockade reduced inflammatory markers and joint swelling, provide early proof that such an approach is feasible.

For the millions of people living with rheumatoid arthritis, the study transforms an old piece of folk wisdom into a concrete molecular map. The journey from a stressful experience to a swollen, painful joint now has identifiable stations: sympathetic nervous system activation, IL-6 release from brown adipose tissue, CXCL1 production by synovial fibroblasts, and neutrophil recruitment through CXCR2. A better understanding of this pathway could guide the development of strategies to anticipate and prevent stress-induced flares, improving disease management and the quality of life of people living with RA. The research also raises broader questions about whether other stress-sensitive inflammatory conditions operate through similar tissue memory mechanisms, a possibility that could reshape how medicine thinks about the body-mind connection in chronic disease.

Subject of Research: Psychological stress reactivates rheumatoid arthritis through an IL-6-dependent pathway linking brown adipose tissue, synovial fibroblasts, and neutrophil recruitment.

Article Title: How psychological stress triggers arthritis flares via an IL-6-dependent pathway

Article References: How psychological stress triggers arthritis flares via an IL-6-dependent pathway. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: rheumatoid arthritis, psychological stress, interleukin-6, brown adipose tissue, synovial fibroblasts, neutrophils, CXCL1, autoimmunity, psychological, stress, triggers, arthritis

The researchers began by asking a deceptively simple question: does the gut microbiome of β-thalassemia mice differ from that of healthy animals in ways that could influence disease severity? To find out, they collected fecal samples from wild-type and β-thalassemia mice and subjected them to 16S rRNA sequencing, a technique that reads the genetic barcodes of bacterial communities to map their composition. The analysis revealed that P. copri stood out as a dominant pro-inflammatory bacterium in the β-thalassemia animals, prompting the team to test whether the microbe was merely a bystander or an active contributor to the disorder’s hallmark iron overload and inflammation.

To answer that question, the investigators designed a four-group experiment that separated the effects of the mutation from the effects of the bacterium. They established wild-type mice, wild-type mice given P. copri, β-thalassemia mice, and β-thalassemia mice given P. copri, delivering the bacterium by intragastric gavage, a controlled oral transplantation technique that bypasses uncertainty about natural colonization. This design allowed the researchers to observe what happens when the microbe is introduced into a system already primed by the genetic disease, and to compare it against the same introduction in healthy animals.

The results were striking. Compared with untreated β-thalassemia mice, those that received P. copri showed elevated serum levels of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6, alongside a decrease in the anti-inflammatory cytokine interleukin-10. At the same time, serum ferritin, a clinical marker of the body’s iron stores, rose, while ferroportin, the membrane protein responsible for exporting iron from cells into the bloodstream, fell. All of these changes reached statistical significance at p < 0.05, indicating that the bacterium was not simply adding noise to the disease picture but actively pushing the animals toward greater iron retention.

The hematological consequences were equally telling. Hemoglobin levels dropped in the P. copri-treated β-thalassemia mice, while erythropoietin and reticulocyte counts climbed. This pattern suggests that the bacterium worsened the already inefficient erythropoiesis that defines β-thalassemia, forcing the body to compensate with higher erythropoietin output and increased production of immature red blood cells. The authors note that P. copri may further aggravate ineffective erythropoiesis and erythrocyte injury in these animals, compounding the central defect of the disorder rather than merely adding a secondary complication.

To understand the molecular mechanism behind these observations, the team turned to the JAK/STAT signaling pathway, a canonical route by which interleukin-6 and related cytokines transmit inflammatory signals from the cell surface to the nucleus. Using quantitative real-time reverse transcription polymerase chain reaction and Western blotting, they measured the expression of glycoprotein 130, the co-receptor that anchors interleukin-6 signaling, along with Janus kinase 1, signal transducer and activator of transcription 3, and the phosphorylated forms of both kinases. In the β-thalassemia mice given P. copri, the expression levels of GP130, the ratio of phosphorylated to total JAK1, and the ratio of phosphorylated to total STAT3 were all upregulated, indicating that the pathway had been switched into a higher gear by the bacterial intervention.

The tissue-level evidence reinforced the molecular findings. Hematoxylin-eosin staining of colonic tissue revealed mucosal damage accompanied by inflammatory cell infiltration in the P. copri-treated β-thalassemia mice, pointing to direct intestinal injury on top of the systemic inflammation. Prussian blue staining, which highlights iron deposits as blue granules under the microscope, showed markedly aggravated iron accumulation in both the liver and the spleen of the treated animals compared with untreated β-thalassemia controls. Together, these histological observations confirmed that the bacterium’s effects were not confined to blood markers but extended to visible organ pathology.

The authors propose that P. copri exacerbates iron overload by triggering inflammatory responses and upregulating hepcidin, the liver-derived hormone that acts as the master regulator of iron homeostasis. Hepcidin binds to ferroportin and causes it to be internalized and degraded, effectively locking iron inside macrophages, hepatocytes, and enterocytes. By elevating interleukin-6, a potent inducer of hepcidin expression, and subsequently activating the JAK/STAT signaling pathway, P. copri appears to set off a cascade that suppresses iron export and traps the metal in tissues, worsening the iron burden that already plagues β-thalassemia patients.

The study’s implications reach beyond the laboratory. β-thalassemia affects populations across the Mediterranean, the Middle East, and Southeast Asia, and iron overload remains a leading cause of morbidity in these patients despite chelation therapy. If gut microbes can modulate hepcidin and iron distribution through immune signaling, then microbiome-targeted interventions, whether through dietary modification, probiotics, or antibiotics, could theoretically complement existing treatments. The finding also adds to a growing body of evidence that the intestinal microbiota is not a passive passenger in hematological disease but an active participant capable of shaping inflammation, erythropoiesis, and metal metabolism.

As with any animal study, the results require careful interpretation before they can inform clinical practice. The mouse model does not fully recapitulate the human disease, and the specific contribution of P. copri in patients with β-thalassemia remains to be established through human cohort studies. Nevertheless, the mechanistic clarity of the work, linking a specific gut bacterium to a specific signaling pathway and a specific clinical problem, offers a concrete starting point for future investigations. The research was supported by the National Natural Science Foundation of China, the Guangxi Ba Gui Scholars Special Project, and the Guangxi Medical and Health Key Discipline Construction Project, and the full article is available open access in Annals of Hematology.

Subject of Research: The role of Prevotella copri in exacerbating iron overload and chronic inflammation in β-thalassemia mice through JAK/STAT pathway activation.

Article Title: Mechanistic insights into how Prevotella copri exacerbates tissue iron retention and chronic inflammation in β-thalassemia mice via activation of the JAK/STAT signaling pathway

Article References: Li, Y., Huang, T., Chen, G., Liu, Z., Li, J., Ke, Z., Li, Y., Song, J., Mo, L., & Zhu, C. (2026). Mechanistic insights into how Prevotella copri exacerbates tissue iron retention and chronic inflammation in β-thalassemia mice via activation of the JAK/STAT signaling pathway. Annals of Hematology. https://doi.org/10.1007/s00277-026-07320-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07320-6

Keywords: Prevotella copri, β-thalassemia, iron overload, JAK/STAT signaling pathway, chronic inflammation, gut microbiome, hepcidin, interleukin-6, ferroportin, ineffective erythropoiesis, Annals of Hematology, Mechanistic

The study included 126 patients with muscle-invasive bladder cancer who underwent radical cystectomy with a Bricker ileal conduit, a urinary diversion technique in which a segment of intestine is used to create a stoma. Sixty-three patients were managed with a 22-element ERAS protocol adapted from ERAS Society guidelines, while 63 historical controls received standard perioperative care. The ERAS pathway combined eight preoperative elements, including patient education, nutritional optimization, carbohydrate loading, and shortened fasting, with seven intraoperative measures such as epidural analgesia, goal-directed fluid therapy, and active maintenance of body temperature, and seven postoperative elements including early feeding, early mobilization, and milestone-based discharge criteria. Many of these components were delivered or coordinated by nursing staff, making the protocol as much a nursing intervention as a surgical one.

To track immune changes, the team drew blood at three standardized timepoints: 24 hours before surgery, 24 hours after surgery, and on postoperative day seven or at discharge. Multiplex flow cytometry quantified cytotoxic CD8-positive T cells, regulatory T cells, and natural killer cells, while a 37-analyte Luminex panel measured inflammatory cytokines and ELISA assays captured soluble immune checkpoint molecules such as soluble PD-L1. The differences between the two groups were striking. In the ERAS cohort, CD8-positive T-cell counts fell by 22.8 percent from baseline in the first 24 hours after surgery, compared with a 41.6 percent decline in the conventional group, a difference that was highly statistically significant. Serum interleukin-6, a key inflammatory cytokine released during surgical stress, averaged 43.2 picograms per milliliter in ERAS patients versus 87.4 picograms per milliliter in conventional patients.

Beyond the cellular counts, the soluble immune landscape also differed. ERAS patients showed lower concentrations of soluble PD-L1 and soluble TIM-3, molecules shed into the bloodstream that are thought to dampen antitumor immunity, and higher levels of interferon-gamma, a cytokine central to cytotoxic immune defense. Natural killer cell activity was also better preserved, at 42.3 percent versus 31.7 percent. By postoperative day seven, several of these measures remained more favorable in the ERAS group, including higher CD8 counts and lower proportions of immunosuppressive regulatory T cells. The authors are careful to note, however, that these timepoint comparisons alone cannot establish a causal effect of ERAS on immune trajectories, since no formal group-by-time mixed-effects analysis was performed.

One of the most intriguing findings is an exploratory four-marker immune index measured 24 hours after surgery, combining CD8-positive T-cell count, interleukin-6, soluble PD-L1, and natural killer cell activity. When the researchers tested this composite score against the risk of infectious complications within 30 days of surgery, it achieved an area under the receiver operating characteristic curve of 0.84, with a 95 percent confidence interval of 0.76 to 0.92. That performance substantially exceeded a reference model based only on ASA score and clinical stage, which reached an AUC of 0.61. Individual markers performed less well, with interleukin-6 alone at 0.76 and CD8 count alone at 0.73, suggesting that the integration of multiple immune dimensions carries the predictive signal.

The team also examined the tumors themselves. Using multiplex immunofluorescence on surgical specimens, they quantified immune cell infiltration in tumor nests, invasive margins, and surrounding stroma. Specimens from the ERAS cohort showed higher densities of CD8-positive tumor-infiltrating lymphocytes in both tumor nests and invasive margins, lower densities of CD68-positive CD163-positive M2-polarized macrophages, and higher ratios of CD8-positive to FoxP3-positive cells, a measure that weighs cytotoxic against regulatory immune activity. Spatial transcriptomics performed on 24 specimens revealed higher expression of cytotoxic effector genes such as GZMB, PRF1, and IFNG, and lower expression of exhaustion markers including TIGIT, LAG3, and PDCD1 in the ERAS group. The immune-inflamed tumor phenotype, characterized by T cells penetrating deep into tumor tissue, was present in 52.4 percent of ERAS specimens versus 28.6 percent of conventional ones.

Here the authors issue an important caution. Because tumor tissue was collected at the time of cystectomy, before any postoperative ERAS component such as early feeding or mobilization could have taken effect, the tumor immune differences are cross-sectional observations rather than evidence that ERAS remodels the tumor microenvironment. They may reflect pre-existing tumor biology, differences in surgical approach, calendar-period effects, or other confounders. Indeed, the ERAS group had shorter operative times, less blood loss, lower transfusion rates, and more frequent minimally invasive surgery, all of which could independently influence both systemic immunity and tumor immune features.

Clinically, the ERAS group fared better on nearly every recovery measure. Time to first flatus was 2.1 days versus 3.4 days, first oral intake occurred at 8.2 hours versus 28.7 hours, and first mobilization at 12.4 hours versus 24.6 hours. Postoperative length of stay averaged 4.8 days compared with 7.2 days, resting pain scores on the first day after surgery were 3.2 versus 5.1 on a ten-point scale, and total hospitalization costs were 22.4 percent lower. The overall rate of 30-day infectious complications was numerically lower in the ERAS group at 19.0 percent versus 33.3 percent, but this difference did not reach conventional statistical significance after recalculation, with a P value of 0.068.

Survival analyses, while exploratory, added another layer. Among patients with available follow-up, descriptive three-year overall survival proportions were 78.1 percent in the ERAS cohort and 68.3 percent in the conventional cohort, though the authors stress these are not formal Kaplan-Meier estimates for the full cohort. In multivariable Cox models, ERAS management was associated with an overall survival hazard ratio of 0.58, and an eight-gene immune signature comprising cytotoxic effectors, exhaustion markers, FOXP3, CD163, and IL6 showed an even stronger association at a hazard ratio of 0.47. Notably, the survival benefit associated with ERAS appeared concentrated in patients whose tumors had high tumor mutational burden, with a hazard ratio of 0.41 in that subgroup and a nominal interaction P value of 0.048.

The authors are unequivocal that these biomarker and survival findings are hypothesis-generating rather than validated. The four-marker index and eight-gene signature were developed and tested in the same retrospective cohort, creating a real risk of overfitting, and only 33 infectious events were available for the predictive analysis. The single-center historical-control design means ERAS exposure is tightly correlated with calendar period, and secular improvements in surgical technique, infection control, and systemic therapy could account for some of the observed differences. Mean follow-up was approximately 24 months, limiting interpretation of three-year outcomes. What the study does establish is a detailed immunological portrait of what happens to the immune system after major cancer surgery under two different care philosophies, and a roadmap for the prospective, contemporaneous trials with longitudinal immune sampling and paired tumor biopsies that will be needed before any of these signals can guide clinical practice.

Subject of Research: Perioperative immunogenomic differences between ERAS-based and conventional nursing care in muscle-invasive bladder cancer patients undergoing radical cystectomy

Article Title: Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer

Article References: Xin, L.-L., Guo, J.-J., Zheng, X.-Y., & Li, Z.-Y. (2026). Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer. Frontiers in Genetics, 17, Article 1967034. https://doi.org/10.3389/fgene.2026.1967034

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1967034

Keywords: bladder cancer, ERAS, radical cystectomy, perioperative immunogenomics, CD8 T cells, tumor immune microenvironment, immune biomarkers, interleukin-6, tumor mutational burden, spatial transcriptomics, nursing care, infectious complications

The research team enrolled 82 participants in a cross-sectional design: 44 people carrying carotid vulnerable plaques, 15 people with carotid stable plaques, and 23 healthy controls. Vulnerable plaques are those with features such as lipid-rich cores, thin or ruptured fibrous caps, or intraplaque hemorrhage, characteristics that mark them as more likely to rupture and trigger embolic events. Stable plaques, by contrast, tend to be fibrotic and calcified, and are considered less likely to shed debris into the bloodstream. All participants underwent brain magnetic resonance imaging with a multi-shell diffusion protocol, a technique that sensitizes the MRI signal to the random motion of water molecules within tissue. Because water diffuses more freely along the length of nerve fibers than across them, the pattern of diffusion reveals the integrity of the brain’s underlying cabling.

The study employed two complementary diffusion modeling approaches. Diffusion tensor imaging, or DTI, the older and more widely used method, characterizes diffusion with a simple ellipsoid model and yields metrics such as fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity. Diffusion kurtosis imaging, or DKI, extends this framework by measuring the degree to which water diffusion deviates from the ideal Gaussian behavior assumed by DTI. This non-Gaussian component, quantified as kurtosis, is thought to be sensitive to tissue complexity at the cellular level, including restrictions imposed by cell membranes, myelin sheaths, and organelles. By combining both modalities in a single multi-shell acquisition, the researchers aimed to strengthen confidence that the abnormalities they detected reflected genuine microstructural injury rather than artifacts of a single model.

To analyze the imaging data, the team applied tract-based spatial statistics, a widely used whole-brain approach that aligns all participants’ images to a common template and projects diffusion metrics onto the centerlines of major white matter tracts. This voxel-wise method allows researchers to detect subtle, spatially extended changes that might escape notice in conventional region-of-interest measurements. The investigators complemented the whole-brain analysis with targeted region-of-interest comparisons across a battery of named tracts, including the corona radiata, the corpus callosum, the internal capsule, the superior longitudinal fasciculus, and the cingulum, among others. Blood samples were collected to measure two systemic inflammatory markers: high-sensitivity C-reactive protein, an acute-phase protein produced by the liver, and interleukin-6, a signaling molecule secreted by immune cells that drives much of the acute-phase response.

The results were striking in their asymmetry. Compared with healthy controls, participants with vulnerable plaques showed widespread white matter microstructural damage, concentrated in the posterior corona radiata and the superior longitudinal fasciculus. The damage pattern was internally consistent: mean diffusivity, axial diffusivity, and radial diffusivity were all elevated, indicating increased freedom of water movement and therefore disruption of the barriers that normally constrain it, while mean kurtosis and axial kurtosis were reduced, consistent with a loss of cellular complexity and architectural order. Radial diffusivity, in particular, is often interpreted as a marker of myelin injury, whereas axial diffusivity changes have been linked to axonal damage. The co-occurrence of these signatures suggests that the vulnerable plaque group carried genuine structural injury in the long fiber pathways that connect distant brain regions.

Participants with stable plaques told a very different story. When the researchers compared the stable plaque group with healthy controls, only a handful of regions showed statistically significant differences in diffusion metrics, and the overall burden of abnormality was far lower than in the vulnerable plaque group. This dissociation is the central finding of the study: two groups of people, both carrying carotid plaques that had never caused symptoms, showed profoundly different brain microstructure depending on the biological character of the plaque itself. The finding implies that the vulnerable plaque is not merely a stroke risk waiting to happen but may be an active source of ongoing, subclinical brain injury.

The inflammatory connection sharpened the picture further. In the vulnerable plaque group, the degree of white matter damage correlated significantly with blood levels of both high-sensitivity C-reactive protein and interleukin-6. Participants with higher systemic inflammatory burden tended to show more severe microstructural abnormalities in the affected tracts. No such correlation emerged in the stable plaque group or in healthy controls, suggesting that the link between inflammation and brain injury is specific to the vulnerable plaque state rather than a general feature of atherosclerosis. The researchers propose a model in which biologically active plaques sustain a state of systemic inflammation, and that inflammation, through mechanisms that may include endothelial dysfunction, microvascular injury, and direct inflammatory signaling across the blood-brain barrier, contributes to the degradation of white matter integrity.

The technical strength of the study lies in its dual-modality design. DTI metrics alone can be confounded by factors such as crossing fibers, partial volume effects, and free water contamination, which can mimic or mask true microstructural change. Kurtosis metrics, being sensitive to non-Gaussian diffusion, provide an independent check on the tensor findings. The fact that both approaches converged on the same tracts, with diffusivity measures rising and kurtosis measures falling in the posterior corona radiata and superior longitudinal fasciculus, strengthens the argument that the observed changes reflect real tissue injury. The posterior corona radiata carries fibers connecting the thalamus and brainstem to the parietal and occipital cortices, while the superior longitudinal fasciculus is one of the brain’s major long association pathways, linking frontal, parietal, and temporal regions. Damage to these tracts has been associated with cognitive slowing, executive dysfunction, and processing speed deficits in other cerebrovascular populations.

The study has limitations inherent to its cross-sectional design. With 44 vulnerable plaque participants, 15 stable plaque participants, and 23 controls, the sample is modest, and the imbalance between plaque subgroups may limit statistical power for detecting subtler differences in the stable group. Cross-sectional data cannot establish whether the white matter changes precede, accompany, or follow the development of plaque vulnerability, nor can they confirm that inflammation is a cause rather than a correlate of the injury. Longitudinal follow-up will be needed to determine whether people with vulnerable plaques and elevated inflammatory markers progress to overt cognitive decline or stroke at higher rates, and whether reducing inflammation, through statins, anti-inflammatory agents, or lifestyle interventions, can halt or reverse the microstructural damage.

Nevertheless, the findings carry practical implications. Carotid ultrasound is already a routine part of stroke risk assessment, and plaque morphology can be characterized noninvasively. If the results are replicated in larger and more diverse cohorts, the combination of plaque vulnerability assessment with diffusion kurtosis imaging and inflammatory biomarker measurement could offer clinicians a way to identify, among the many people with silent carotid disease, the subset whose brains are already being affected. That would represent a shift from treating asymptomatic carotid atherosclerosis as a single condition toward recognizing it as a spectrum in which plaque biology, systemic inflammation, and brain integrity are intertwined. For now, the study stands as an early but compelling piece of evidence that the brain keeps score of what the carotid artery is doing, even when the patient feels nothing at all.

Subject of Research: White matter microstructural changes associated with vulnerable versus stable asymptomatic carotid plaques and their relationship to inflammatory biomarkers

Article Title: Plaque vulnerability-specific white matter microstructural integrity loss in asymptomatic carotid atherosclerosis and its link to inflammatory biomarkers: a dual-modality DTI/DKI study

Article References: Wang, D., Leng, Y., Liu, W. V., Zhang, Y., Liao, W., & Yang, S. (2026). Plaque vulnerability-specific white matter microstructural integrity loss in asymptomatic carotid atherosclerosis and its link to inflammatory biomarkers: a dual-modality DTI/DKI study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02939-3

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02939-3

Keywords: carotid atherosclerosis, vulnerable plaque, white matter, diffusion tensor imaging, diffusion kurtosis imaging, inflammation, C-reactive protein, interleukin-6, stroke risk, brain imaging, microstructural integrity, cerebrovascular disease